EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia

Emmanuel Mignot iD, Richard K Bogan iD, Helene Emsellem, Nancy Foldvary-Schaefer, Melissa Naylor, Rachel Neuwirth, Hélène Faessel, Todd Swick, Tina Olsson

SLEEP · 08.09.2023 · 46 (9)

DOI: 10.1093/sleep/zsad049 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift SLEEP, online erschienen am 08.03.2023. Verfasst von Emmanuel Mignot und 8 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Department of Psychiatry and Behavioral Medicine, Center for Sleep Sciences and Medicine, Stanford University Medical School, Palo Alto, CA,…. Hauptthemen laut MEDLINE: Idiopathic Hypersomnia, Disorders of Excessive Somnolence. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Millennium Pharmaceuticals Inc, Takeda Development Center Americas, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objectives Idiopathic hypersomnia (IH) is a chronic disorder characterized by excessive daytime sleepiness unexplained by another disorder or drug/medication use. Although the orexin system plays a role in sleep-wake regulation, orexin A levels in the cerebrospinal fluid are normal in people with IH. This phase 1b, randomized, placebo-controlled, crossover study aimed to investigate the safety, pharmacokinetics, and pharmacodynamics of danavorexton, a small-molecule orexin-2 receptor agonist, in adults with IH.

Methods

Adults with IH aged 18–75 years were randomized to one of two treatment sequences of single intravenous infusions of danavorexton 112 mg and placebo. Pharmacodynamic endpoints included the maintenance of wakefulness test (MWT), the Karolinska Sleepiness Scale (KSS), and the psychomotor vigilance task (PVT). Adverse events were monitored throughout the study period.

Results

Of 28 randomized participants, 12 (44.4%) had a treatment-emergent adverse event (TEAE) and 10 (37.0%) had a TEAE considered related to study drug, most of which were mild or moderate. Four participants (18.2%) had urinary TEAEs while receiving danavorexton, all of which were mild in severity. There were no deaths or TEAEs leading to discontinuation. Improvements in MWT, KSS, and PVT scores were observed with danavorexton compared to placebo. Following drug administration, a mean sleep latency of 40 min (maximum value) was observed during the MWT within 2 h of danavorexton infusion in most participants.

Conclusions

A single infusion of danavorexton improves subjective and objective excessive daytime sleepiness in people with IH with no serious TEAEs, indicating orexin-2 receptor agonists are promising treatments for IH. Clinical Trial: Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04091438

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic HypersomniaDisorders of Excessive SomnolenceHumansAdultModafinilOrexinsCross-Over StudiesBenzhydryl CompoundsWakefulness

Stichwörter der Autor:innen

danavorextonexcessive daytime sleepinessidiopathic hypersomniaorexin type 2 receptor agonist

Substanzen

ModafinilOrexinsBenzhydryl Compounds

Autor:innen und Institutionen

  • Stanford Department of Psychiatry and Behavioral Medicine, Center for Sleep Sciences and Medicine, Stanford University Medical School, Palo Alto, CA, USA.
  • Bogan Sleep Consultants, LLC, Columbia, SC, USA.
  • The Center of Sleep & Wake Disorders, Chevy Chase, MD, USA.
  • Department of Neurology, Sleep Disorders Center, Cleveland Clinic, Cleveland, OH, USA.
  • Takeda Development Center Americas, Inc., Lexington, MA, USA.

ORCID-Profile: Emmanuel Mignot, Richard K Bogan

Förderung

  • Millennium Pharmaceuticals Inc
  • Takeda Development Center Americas, Inc

Zitieren

APA

Mignot, E., Bogan, R. K., Emsellem, H., Foldvary-Schaefer, N., Naylor, M., Neuwirth, R., Faessel, H., Swick, T., & Olsson, T. (2023). Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia. SLEEP, 46(9). https://doi.org/10.1093/sleep/zsad049

Vancouver

Mignot E, Bogan RK, Emsellem H, Foldvary-Schaefer N, Naylor M, Neuwirth R, et al. Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia. SLEEP. 2023;46(9). doi:10.1093/sleep/zsad049

BibTeX
@article{Mignot2023,
  author = {Mignot, Emmanuel and Bogan, Richard K and Emsellem, Helene and Foldvary-Schaefer, Nancy and Naylor, Melissa and Neuwirth, Rachel and Faessel, Hélène and Swick, Todd and Olsson, Tina},
  title = {Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia},
  journal = {SLEEP},
  year = {2023},
  volume = {46},
  number = {9},
  doi = {10.1093/sleep/zsad049}
}
Kostenlos starten →